Sign In

Oleg Sofrygin, PhD

People

Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

(510) 891-3748 (phone)
oleg.sofrygin@kp.org


Oleg Sofrygin, PhD, is a Biostatistician/Research Scientist I at the Kaiser Permanente Northern California Division of Research. He holds a concurrent appointment as a Postdoctoral Scholar in Biostatistics at the University of California, Berkeley. His work at U.C. Berkeley is supported by the Bill and Melinda Gates Foundation, Healthy Birth, Growth, and Development Knowledge Initiative (HBGDki). Dr. Sofrygin’s research focuses on the development of statistical methods for data-adaptive estimation of causal treatment effects in observational studies. He is interested in developing and disseminating open-source, machine-learning-based statistical software for analyzing longitudinal data. He is currently applying his software skills in the evaluation of the comparative effectiveness of diabetes treatments from large-scale, longitudinal electronic health record data. Dr. Sofrygin’s other research interests include high-performance statistical computing, the estimation of causal effects of interventions in network-connected communities, and the design of simulation studies for causal inference. Dr. Sofrygin received his PhD in Biostatistics from the University of California, Berkeley. His dissertation work focused on semi-parametric estimation of causal effects in network-dependent data.

Current Position(s):

  • Research Scientist I, Division of Research, Kaiser Permanente Northern California
  • Postdoctoral Scholar, Biostatistics, University of California, Berkeley

Section Affiliations:

    Related Website(s):

    No results found matching criteria
    No results found matching criteria

    simcausal R Package: Conducting Transparent and Reproducible Simulation Studies of Causal Effect Estimation with Complex Longitudinal Data

    Author(s): Sofrygin O; van der Laan MJ; Neugebauer R

    J Stat Softw. 2017;81. Epub 2017-10-16.

    PubMed abstract

    simcausal R Package: Conducting Transparent and Reproducible Simulation Studies of Causal Effect Estimation with Complex Longitudinal Data

    Author(s): Oleg Sofrygin; Mark J. van der Laan; Romain Neugebauer

    ​Sofrygin O, van der Laan MJ and Neugebauer R (2017). simcausal R Package: Conducting Transparent and Reproducible Simulation Studies of Causal Effect Estimation with Complex Longitudinal Data. Journal of Statistical Software, 81(2), pp. 1–47. doi: 10.18637/jss.v081.i02

    PubMed abstract

    Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia.

    Author(s): Hatswell AJ; Thompson GJ; Maroudas PA; Sofrygin O; Delea TE;

    ​Cost Eff Resour Alloc. 2017 May 26;15:8. doi: 10.1186/s12962-017-0071-x. eCollection 2017.

    PubMed abstract

    Semi-Parametric Estimation and Inference for the Mean Outcome of the Single Time-Point Intervention in a Causally Connected Population.

    Author(s): Sofrygin O; van der Laan MJ;

    ​J Causal Inference. 2017 Mar;5(1). pii: 20160003. doi: 10.1515/jci-2016-0003. Epub 2016 Nov 29.

    PubMed abstract

    Long-term outcomes among African-American and white women with breast cancer: what is the impact of comorbidity?

    Author(s): Izano M; Satariano WA; Tammemagi MC; Ragland D; Moore DH; Allen E; Naeim A; Sehl ME; Hiatt RA; Kerlikowske K; Sofrygin O; Braithwaite D;

    ​J Geriatr Oncol. 2014 Jul;5(3):266-75. doi: 10.1016/j.jgo.2014.02.003. Epub 2014 Mar 5.

    PubMed abstract

    Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.

    Author(s): Weycker D; Sofrygin O; Seefeld K; Deeter RG; Legg J; Edelsberg J

    ​BMC Health Serv Res. 2013 Feb 13;13:60. doi: 10.1186/1472-6963-13-60.

    PubMed abstract

    Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.

    Author(s): Delea TE; Tappenden P; Sofrygin O; Browning D; Amonkar MM; Karnon J; Walker MD; Cameron D

    ​Eur J Health Econ. 2012 Oct;13(5):589-603. doi: 10.1007/s10198-011-0323-1. Epub 2011 Jun 24.

    PubMed abstract

    Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.

    Author(s): Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M

    ​Clin Breast Cancer. 2010 Aug 1;10(4):267-74. doi: 10.3816/CBC.2010.n.034.

    PubMed abstract

    Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.

    Author(s): Delea TE; Sofrygin O; Palmer JL; Lau H; Munk VC; Sung J; Charney A; Parving HH; Sullivan SD

    ​J Am Soc Nephrol. 2009 Oct;20(10):2205-13. doi: 10.1681/ASN.2008111144. Epub 2009 Sep 17.

    PubMed abstract

    Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq.

    Author(s): Weycker D; Sofrygin O; Kemner JE; Pelton SI; Oster G

    ​Vaccine. 2009 Aug 6;27(36):4930-7. doi: 10.1016/j.vaccine.2009.06.025. Epub 2009 Jun 23.

    PubMed abstract

    Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.

    Author(s): Vera-Llonch M; Dukes E; Rejas J; Sofrygin O; Mychaskiw M; Oster G

    ​Eur J Health Econ. 2010 Feb;11(1):35-44. doi: 10.1007/s10198-009-0160-7. Epub 2009 Jun 9.

    PubMed abstract

    Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.

    Author(s): Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G

    ​J Rheumatol. 2008 Sep;35(9):1745-53. Epub 2008 Jul 15.

    PubMed abstract

    Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.

    Author(s): Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G

    ​Rheumatology (Oxford). 2008 Apr;47(4):535-41. doi: 10.1093/rheumatology/ken007.

    PubMed abstract

    Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.

    Author(s): Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD

    ​Transfusion. 2007 Oct;47(10):1919-29.

    PubMed abstract

    Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.

    Author(s): Delea TE; El-Ouagari K; Karnon J; Sofrygin O

    ​Breast Cancer Res Treat. 2008 Apr;108(3):375-87. Epub 2007 Jul 26.

    PubMed abstract

    Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

    Author(s): Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V

    ​Clin Breast Cancer. 2007 Jun;7(8):608-18.

    PubMed abstract

    Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.

    Author(s): Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD

    Pharmacoeconomics. 2007;25(4):329-42.

    PubMed abstract